Breast Cancer Innovator Atossa Genetics Adds Former Pfizer & Janssen Pharmacuetica NV Execs To SAB
Seattle based Atossa Genetics Inc. (ATOS) (“Atossa”) is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. This week, Atossa appointed two additional pharmaceutical executives to its strategic advisory board (“SAB”) as they named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive. The board is positioned to play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs.
Steven Quay, Ph.D., MD, President and CEO of Atossa stated, “We are very excited to have both Dr. Jawadeker and Dr. Shetty join our advisory board. Each of these lauded industry veterans brings unique sets of talents and experiences to our company. Their insights and direction will be invaluable in developing our strategic initiatives to advance our therapeutics.
Dr. Mak Jawadekar’s professional career at Pfizer, Inc. spanned 28 consecutive years, most recently as a Director, Portfolio Management. During his career at Pfizer, he was responsible for the Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies and has extensive experience in creating and cultivating external partnerships and alliances in this area. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. Mak was honored with an honorary D.Sc. degree by DYP Mumbai University, recommended by the President of India in Feb 2011. His years of experience with Pfizer Global R&D includes Solids R&D, Drug Product Formulation/ Dosage Form/Drug Delivery development, Clinical Trials Supply Manufacturing, and Scale-up and Technology Transfer & Research Pharmacy functions. At Pfizer he was also a bench scientist, working on many challenging commercial formulations which became multibillion-dollar products.
Dr. Shetty spent his 40-plus year career at Janssen Pharmaceutica NV in Belgium (a Johnson & Johnson company) in which he drove the expansion of the Janssen Group of Companies through geographical expansion, new product introduction, and significant market share growth. In his prior capacity as President of Janssen Pharmaceutica USA, Dr. Shetty launched Janssen USA into the largest pharmaceutical market. Currently, Dr. Shetty is Chairman of the Belgium-based Flemish Institute of Biotechnology, one of the world’s top-ten research institutions. In 2008, he was awarded the title of Baron by the King of Belgium and in 2004 was elected Manager of the Year by Trends/Flemish Management Association. He is a member of the Board of Directors at Agile Therapeutics, Actinium Pharmaceuticals, and is a member of the Board of Trustees of Carnegie Mellon University.